Obstructive Sleep Apnoea and Cardiac Arrhythmias (OSCA)
Obstructive Sleep Apnea, Cardiovascular Diseases, Arrhythmia
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring Atrial Fibrillation, Obstructive Sleep Apnea, Implantable Loop Recorder, Extended Cardiac Monitoring, Matrix Metalloproteinase-9, Interleukin-6, Tumour Necrosis Factor-Alpha, High sensitivity C-Reactive Protein, High sensitivity Troponin-T, Fibroblast Growth Factor-23, Heart Rate Variability, N-Terminal pro B-type Natriuretic Peptide
Eligibility Criteria
Inclusion Criteria:
- Patients with moderate to severe sleep apnoea who require CPAP as standard care (AHI >15)
- Patients between the age of 18 and 75
Exclusion Criteria:
- Patients with a diagnosis of atrial fibrillation (AF), atrial flutter and/or ventricular tachycardia (VT)
- Patients with an ILR already in-situ or an established indication for ILR
- Patients with a palliative diagnosis i.e. life expectancy less than 3 years
- Patients who lack capacity
Sites / Locations
- University Hospital Coventry & Warwickshire
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
ILR
No ILR
Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
Participants who will not get the Implantable Loop Recorder (Reveal-LINQ).